Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) FCF Margin: 2020-2025

Historic FCF Margin for Relay Therapeutics (RLAY) over the last 3 years, with Jun 2025 value amounting to -8,166.47%.

  • Relay Therapeutics' FCF Margin was N/A to -8,166.47% in Q2 2025 from the same period last year, while for Jun 2025 it was -1,427.18%, marking a year-over-year change of. This contributed to the annual value of -2,509.49% for FY2024, which is 131775.00% down from last year.
  • As of Q2 2025, Relay Therapeutics' FCF Margin stood at -8,166.47%, which was down 752.11% from -958.38% recorded in Q1 2025.
  • In the past 5 years, Relay Therapeutics' FCF Margin ranged from a high of 8,930,600.00% in Q4 2023 and a low of -58,910.92% during Q2 2023.
  • In the last 3 years, Relay Therapeutics' FCF Margin had a median value of -958.38% in 2025 and averaged 1,261,598.74%.
  • Its FCF Margin has fluctuated over the past 5 years, first tumbled by 49,765,517bps in 2021, then surged by 895,407,628bps in 2023.
  • Over the past 5 years, Relay Therapeutics' FCF Margin (Quarterly) stood at -7,158.20% in 2021, then crashed by 1,631,808bps to -23,476.28% in 2022, then spiked by 895,407,628bps to 8,930,600.00% in 2023, then spiked by 3,003,022bps to -520.67% in 2024, then plummeted by 43,771bps to -8,166.47% in 2025.
  • Its FCF Margin was -8,166.47% in Q2 2025, compared to -958.38% in Q1 2025 and -520.67% in Q1 2024.